Red blood membrane camouflaging Bismuth nanoflowers designed for radio-photothermal therapy in lung cancer
Radio-photothermal therapy is an effective modality for cancer treatment. To overcome the radio-resistance in the hypoxic microenvironment and improve the sensitivity of radiotherapy, metal nanoparticles, and radio-photothermal therapy are widely used in the research of improving the curative effect and reducing the side effects of radiotherapy. Here, we developed red blood membrane camouflaging bismuth nanoflowers (RBCM-BNF) with outstanding physiological stability and biodegradability for lung tumours. In vitro data proved that the RBCM-BNF had the greatest cancer cell-killing ability combined with X-ray irradiation and photo-thermal treatment. Meanwhile, in vivo studies revealed that RBCM-BNF can alleviate the hypoxic microenvironment and promote tumour cell apoptosis by inhibiting HIF-1α expression and increasing caspase-3 expression. Therefore, RBCM-BNF had a good radio-sensitising effect and might be a promising biomimetic nanoplatform as a therapeutic target for cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of drug targeting - (2024) vom: 21. März, Seite 1-13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Chang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomimetic delivery |
|---|
| Anmerkungen: |
Date Revised 21.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/1061186X.2024.2329110 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369596021 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369596021 | ||
| 003 | DE-627 | ||
| 005 | 20240322000536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1061186X.2024.2329110 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369596021 | ||
| 035 | |a (NLM)38469874 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Chang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Red blood membrane camouflaging Bismuth nanoflowers designed for radio-photothermal therapy in lung cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Radio-photothermal therapy is an effective modality for cancer treatment. To overcome the radio-resistance in the hypoxic microenvironment and improve the sensitivity of radiotherapy, metal nanoparticles, and radio-photothermal therapy are widely used in the research of improving the curative effect and reducing the side effects of radiotherapy. Here, we developed red blood membrane camouflaging bismuth nanoflowers (RBCM-BNF) with outstanding physiological stability and biodegradability for lung tumours. In vitro data proved that the RBCM-BNF had the greatest cancer cell-killing ability combined with X-ray irradiation and photo-thermal treatment. Meanwhile, in vivo studies revealed that RBCM-BNF can alleviate the hypoxic microenvironment and promote tumour cell apoptosis by inhibiting HIF-1α expression and increasing caspase-3 expression. Therefore, RBCM-BNF had a good radio-sensitising effect and might be a promising biomimetic nanoplatform as a therapeutic target for cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a RBCM-BNF | |
| 650 | 4 | |a biomimetic delivery | |
| 650 | 4 | |a one-pot synthesis | |
| 650 | 4 | |a radio-photothermal therapy | |
| 650 | 4 | |a radiosensitizers | |
| 650 | 4 | |a tumor microenvironment | |
| 700 | 1 | |a Zhang, Yuanyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Huo, Meirong |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d 1996 |g (2024) vom: 21. März, Seite 1-13 |w (DE-627)NLM074733958 |x 1029-2330 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:03 |g pages:1-13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/1061186X.2024.2329110 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 03 |h 1-13 | ||